Ovarian Cancer Awareness Month 2018

Added

Ovarian cancer is the biggest gynaecological killer of UK women, with UK survival rates amongst the worst in Europe. March is Ovarian Cancer Awareness Month.

Ovarian cancer is the fourth most common form of cancer death in women, after breast, lung and bowel cancer. However, the average GP will see only one case of ovarian cancer every five years.

11 women die in the UK every day from ovarian cancer. Awareness of ovarian cancer is low, both amount women and GPs. Three quarters of women are diagnosed once the cancer has already spread, making treatment more difficult. That is why awareness is so important, to drive forward improvements in detection, treatment and ultimately survival.

“Enough is enough, this March Start Making Noise so we can make sure women have the best chances of survival.”

Ovarian cancer in numbers:

About 7,300 women are diagnosed each year in the UK

4,100 women lose their lives each year – that’s 11 women every day

A woman in the UK has a one in 50 chance of being diagnosed with ovarian cancer in her lifetime.

When a woman is diagnosed at the earliest stage, her chance of surviving ovarian cancer for five years or more double from just 46 per cent to more than 90 per cent

Nearly half of GPs (44 per cent) mistakenly believe symptoms only present in the later stages of ovarian cancer

Just one in five UK women (20 per cent) can name bloating as one of the main symptoms of ovarian cancer

Almost half of women (45 per cent) must wait three months or more from first visiting their GP to getting a correct diagnosis

Over a quarter of women with ovarian cancer (26 per cent) are diagnosed through an emergency presentation such as Accident and Emergency

One third (31 per cent) of women mistakenly think the cervical screening programme would detect ovarian cancer

Background: In order to validate if the test result of the Chemotherapy Resistance Test (CTR-Test) is able to predict the resistances or sensitivities of tumors in ovarian cancer patients to drugs, the CTR-Test result and...

Exosomes are nanoparticles(40-100 nm) secreted by most cells in the body, which can be isolated from several types of extracellular fluids. It has been shown that exosomes play a key role in intercellular communication...

The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...

Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib...

This study will investigate if the drug midostaurin taken orally twice daily is effective and safe in treating patients with aggressive systemic mastocytosis or mast cell leukemia with or without an additional hematological neoplasm.

This guideline provides recommendations based on current evidence for best practice in screening and the role of prophylactic salpingo-oophorectomy; diagnosis; surgical management; chemotherapy; follow up; management...